MedPath

Diphenhydramine

Generic Name
Diphenhydramine
Brand Names
Acetadryl, Advil PM, Aleve PM, Allegra Cooling Relief Anti-itch, Banophen, Benadryl, Benadryl Itch Stopping, Benadryl-D Allergy and Sinus, Calagel, Damylin With Codeine, Dimetapp Nighttime Cold & Congestion, Diphen, Diphenhist, Diphenist, Excedrin PM Triple Action, Goody's PM, Legatrin PM, Motrin PM, Nytol, Nytol Quickgels, Percogesic Reformulated Jan 2011, Siladryl, Simply Sleep, Sleepinal, Sominex, Triaminic Night Time Cold & Cough, Tylenol PM, Unisom, Unisom Sleep, Vanamine, Wal-dryl, Wal-som (doxylamine), Zzzquil
Drug Type
Small Molecule
Chemical Formula
C17H21NO
CAS Number
58-73-1
Unique Ingredient Identifier
8GTS82S83M
Background

Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes . However, it also has antiemetic, antitussive, hypnotic, and antiparkinson properties . As histamine receptors exist both peripherally and in the central nervous system, diphenhydramine has been shown to cause sedation due to its competitive antagonism of histamine H1 receptors within the central nervous system . While its use in allergy therapy can sometimes fall out of favor due to its sedative effect, diphenhydramine has been repurposed for use within many non-prescription over-the-counter sleep aids and cough-and-cold medications that have been marketed for "night time" use .

Diphenhydramine is also used in combination with 8-chlorotheophylline as the anti-nausea drug Dimenhydrinate where it is utilized primarily for its antagonism of H1 histamine receptors within the vestibular system .

Diphenhydramine has also been shown to be implicated in a number of neurotransmitter systems that affect behaviour including dopamine, norepinephrine, serotonin, acetylcholine, and opioid . As a result, diphenhydramine is being investigated for its anxiolytic and anti-depressant properties.

Indication

Diphenhydramine is a first-generation histamine H1 receptor antagonist (H1 antihistamine) that is widely available as a non-prescription, over-the-counter (OTC) medication. As an OTC medication, diphenhydramine is typically formulated as tablets and creams indicated for use in treating sneezing, runny nose, itchy/watery eyes, itching of nose or throat, insomnia, pruritis, urticaria, insect bites/stings, allergic rashes, and nausea .

Additionally, when the use of oral diphenhydramine is impractical, there are also prescription-only formulations such as diphenhydramine injection products that are effective in adults and pediatric patients (other than premature infants and neonates) for:

i) the amelioration of allergic reactions to blood or plasma, in anaphylaxis as an adjunct to epinephrine and other standard measures after acute allergic reaction symptoms have been controlled, and for other uncomplicated allergic conditions of the immediate type when oral therapy is impossible or contraindicated ;

ii) the active treatment of motion sickness ; and

iii) use in parkinsonism when oral therapy is impossible or contraindicated, as follows: parkinsonism in the elderly who are unable to tolerate more potent agents; mild cases of parkinsonism in other age groups, and in other cases of parkinsonism in combination with centrally acting anticholinergic agents .

Associated Conditions
Allergic Reaction, Allergic Rhinitis (AR), Allergic cough, Allergy to Tree Pollen, Anaphylaxis, Angioedema, Common Cold, Conjunctival irritation, Cough, Cough Variant Asthma, Cough caused by Common Cold, Eye allergy, Fever, Insect Bites, Insect Stings, Insomnia, Irritative cough, Itching of the nose, Itching of the throat, Motion Sickness, Nasal Congestion, Oral Mucositis, Pain, Parkinsonian Syndromes, Productive cough, Pruritus, Rash, Rhinorrhoea, Sinus Congestion, Sinus headache, Skin Irritation, Sneezing, Sunburn, Symptoms of Acute Bronchitis Accompanied by Coughing, Upper respiratory tract hypersensitivity reaction, site unspecified, Urticaria, Cold or flu syndrome, Dermatographism, Dry cough, Watery itchy eyes
Associated Therapies
Airway secretion clearance therapy, Expectorant

Effect of Benadryl Sedation During ERCP or EUS

Phase 1
Withdrawn
Conditions
Gallbladder Disease
Gallstones
Pancreatitis
Jaundice
Abdominal Pain
First Posted Date
2005-10-17
Last Posted Date
2015-09-18
Lead Sponsor
University of Rochester
Registration Number
NCT00240123

A Phase 1-2 Trial of Cetuximab in Combination With Oxaliplatin, Capecitabine, and Radiation Therapy Followed by Surgery for Locally-advanced Rectal Cancer

Phase 1
Terminated
Conditions
Rectal Cancer
Colo-rectal Cancer
Interventions
First Posted Date
2005-09-27
Last Posted Date
2017-12-08
Lead Sponsor
George Albert Fisher
Target Recruit Count
23
Registration Number
NCT00226941
Locations
🇺🇸

Stanford University School of Medicine, Stanford, California, United States

Treatment of Orthostatic Hypotension in Autonomic Failure

First Posted Date
2005-09-22
Last Posted Date
2017-01-18
Lead Sponsor
Vanderbilt University
Target Recruit Count
389
Registration Number
NCT00223691
Locations
🇺🇸

Vanderbilt University, Nashville, Tennessee, United States

Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD

Phase 2
Completed
Conditions
Leukemia, Mast-Cell
Mantle-cell Lymphoma
Interventions
First Posted Date
2005-09-16
Last Posted Date
2017-11-28
Lead Sponsor
Stanford University
Target Recruit Count
36
Registration Number
NCT00186628
Locations
🇺🇸

Stanford University School of Medicine, Stanford, California, United States

A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus

Phase 2
Completed
Conditions
Lupus Erythematosus, Systemic
Interventions
First Posted Date
2005-08-30
Last Posted Date
2019-08-20
Lead Sponsor
Genentech, Inc.
Target Recruit Count
262
Registration Number
NCT00137969
Locations
🇺🇸

Univ of Calif., Los Angeles; Rheumatology, Los Angeles, California, United States

🇺🇸

Cedars-Sinai Medical Center, Los Angeles, California, United States

🇺🇸

Emory Uni ; Division of Rheumatology, Atlanta, Georgia, United States

and more 62 locations

Post Burn Pruritus Study in Patients Undergoing Wound Healing

Not Applicable
Completed
Conditions
Itching
Interventions
First Posted Date
2005-08-29
Last Posted Date
2008-07-28
Lead Sponsor
United States Army Institute of Surgical Research
Target Recruit Count
36
Registration Number
NCT00137202
Locations
🇺🇸

US Army Institute of Surgical Research, Fort Sam Houston, Texas, United States

Combination Immunosuppressive Therapy to Prevent Kidney Transplant Rejection in Adults

First Posted Date
2004-03-02
Last Posted Date
2018-06-29
Lead Sponsor
University of Wisconsin, Madison
Target Recruit Count
10
Registration Number
NCT00078559
Locations
🇺🇸

University of Wisconsin - Department of Medicine, Madison, Wisconsin, United States

Lymphocyte Depletion and Stem Cell Transplantation to Treat Severe Systemic Lupus Erythematosus

Phase 2
Completed
Conditions
Lupus Erythematosus, Systemic
Interventions
Biological: Rituxan (rituximab)
Biological: filgrastim
Other: immunologic technique
Other: laboratory biomarker analysis
Procedure: autologous hematopoietic stem cell transplantation
First Posted Date
2004-02-03
Last Posted Date
2021-01-05
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
9
Registration Number
NCT00076752
Locations
🇺🇸

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

BMS 247550 to Treat Kidney Cancer

Phase 2
Completed
Conditions
Renal Cell Carcinoma
Interventions
First Posted Date
2002-02-21
Last Posted Date
2012-08-20
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
102
Registration Number
NCT00030992
Locations
🇺🇸

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Controlled Clinical Trial of Antiviral Cytotoxic T Lymphocyte (CTL) Infusion Following Combination Antiretroviral Drug Therapy for Asymptomatic HIV-1 Infection

Not Applicable
Terminated
Conditions
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2016-12-14
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
16
Registration Number
NCT00000875
Locations
🇺🇸

The Ctr For Blood Research Inc, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath